Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington et al. · Journal of Clinical Oncology · 2014 · 5.3K citations · Full text

Surgical Oncology, Oncologic Imaging, Cancer Management +22

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hervé Tilly, María Gomes da Silva, Umberto Vitolo et al. · Annals of Oncology · 2015 · 900 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +7

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al. · Journal of Clinical Oncology · 2017 · 737 citations · Full text

Immunology, Pathology, Pharmacotherapy +17

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Wei Ding, Betsy LaPlant, Timothy G. Call et al. · Blood · 2017 · 411 citations · Full text

Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody.

Debra A. Budwit-Novotny, Kenneth S. McCarty, Edwin B. Cox et al. · PubMed · 1986 · 388 citations

Endometrial Adenocarcinoma, Hormonal Receptor, Uterine Receptivity +11